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Detecting the presence of prostate cancer (PCa) and distinguishing low- or intermediate-
risk disease from high-risk disease early, and without the need for potentially unnecessary
invasive biopsies remains a significant clinical challenge. The aim of this study is to
determine whether the T and B cell phenotypic features which we have previously
identified as being able to distinguish between benign prostate disease and PCa in
asymptomatic men having Prostate-Specific Antigen (PSA) levels < 20 ng/ml can also be
used to detect the presence and clinical risk of PCa in a larger cohort of patients whose
PSA levels ranged between 3 and 2617 ng/ml. The peripheral blood of 130 asymptomatic
men having elevated Prostate-Specific Antigen (PSA) levels was immune profiled using
multiparametric whole blood flow cytometry. Of these men, 42 were subsequently
diagnosed as having benign prostate disease and 88 as having PCa on biopsy-based
evidence. We built a bidirectional Long Short-TermMemory Deep Neural Network (biLSTM)
model for detecting the presence of PCa in men which combined the previously-identified
phenotypic features (CD8+CD45RA-CD27-CD28- (CD8+ Effector Memory cells),
CD4+CD45RA-CD27-CD28- (CD4+ Effector Memory cells), CD4+CD45RA+CD27-CD28-
(CD4+ Terminally Differentiated Effector Memory Cells re-expressing CD45RA), CD3-CD19+
(B cells), CD3+CD56+CD8+CD4+ (NKT cells) with Age. The performance of the PCa
presence ‘detection’ model was: Acc: 86.79 ( ± 0.10), Sensitivity: 82.78% (± 0.15);
Specificity: 95.83% (± 0.11) on the test set (test set that was not used during training
and validation); AUC: 89.31% (± 0.07), ORP-FPR: 7.50% (± 0.20), ORP-TPR: 84.44%
(± 0.14). A second biLSTM ‘risk’ model combined the immunophenotypic features with
PSA to predict whether a patient with PCa has high-risk disease (defined by the D’Amico
Risk Classification) achieved the following: Acc: 94.90% (± 6.29), Sensitivity: 92% (± 21.39);
Specificity: 96.11 (± 0.00); AUC: 94.06% (± 10.69), ORP-FPR: 3.89% (± 0.00),org December 2021 | Volume 12 | Article 7868281
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Frontiers in Immunology | www.frontiersin.ORP-TPR:92% (± 21.39). The ORP-FPR for predicting the presence of PCa when
combining FC+PSA was lower than that of PSA alone. This study demonstrates that AI
approaches based on peripheral blood phenotyping profiles can distinguish between
benign prostate disease and PCa and predict clinical risk in asymptomatic men having
elevated PSA levels.Keywords: prostate cancer, predictive modeling, immunophenotyping data, flow cytometry, PSA level,
computational analysis, machine learningINTRODUCTION
Currently, diagnosing prostate cancer (PCa) primarily relies on
painful invasive biopsies which put ~5% of men at risk of
developing life-threatening infections, such as urosepsis. As
biopsy results are not definitive, there is a significant risk of
misdiagnosis, over-treatment, and under-treatment. It is
therefore imperative to avoid unnecessary biopsies and more
accurately diagnose the presence of PCa and, if present, its
clinical significance.
In a landmark study, Stamey et al. performed the first large-
scale analysis of serum PSA as a prostate cancer biomarker in
1987, convincingly demonstrating that PSA was more sensitive
than prostate specific acid phosphatase (PSAP)/prostatic acid
phosphatase (PAP) for monitoring the disease (1). They showed
that PSA levels increased with advancing clinical stage and was
useful for detecting disease recurrence after curative therapy (1).
In 1991, Catalona et al. demonstrated that the combination of a
serum PSA measurement ≥4.0 ng/ml with other clinical findings,
such as the results of a DRE, improved detection of prostate
cancer in a prospective study of 1653 healthy men with no
history of cancer (2).
Although the clinical introduction of the Prostate-Specific
Antigen (PSA) test in 1986 increased the early diagnosis of
localised PCa, elevated levels of PSA do not necessarily
indicate the presence of disease, as PSA levels can be raised by
prostatitis, other localised infections, benign hyperplasia and/or
other factors such as physical stress. It is also the case that 15% of
men with PSA levels in the normal range typically have PCa, with
a further 15% of these cancers being high‐grade (https://
prostatecanceruk.org/prostate-information/prostate-tests/
psa-test).
Findings from a study involving 419,582 British men aged 50
to 69 years - the Cluster Randomized Trial of PSA Testing for
Prostate Cancer (CAP), which was conducted at 573 primary
care practices across the United Kingdom, do not support single
PSA testing for population-based screening and suggest that
asymptomatic men should not be routinely tested to avoid
unnecessary anxiety and treatment (3). However, in contrast to
the CAP study, the 16-year follow-up of the European
Randomized Study of Screening for Prostate Cancer (ERSPC)
which was launched in 1993 and was the world’s largest
randomized controlled trial evaluating the effect of PSA
screening on PCa mortality involving men aged between 50
and 69 has reported PSA screening to significantly reduce PCa-
related mortality (4). Given its poor diagnostic specificity, PSA-org 2based PCa screening is not currently supported by the UK
National Health Service (NHS) or promoted in any other country.
So, how do we improve the diagnosis of PCa beyond the
utilisation of PSA and digital rectal examination (DRE) alone
given that measuring blood PSA levels lacks specificity and the
DRE lacks both sensitivity and specificity? PSA and DRE
measurements do not necessarily differentiate between
clinically significant PCa, which requires treatment, and
indolent cancer, for which the current recommendation is
active surveillance. The challenge over the past two decades
has therefore not only been to improve the diagnostic yield of
PCa, but also to develop new approaches for more specifically
distinguishing between benign prostate disease and PCa and,
arguably more importantly, between low-risk disease which
requires no treatment and clinically significant disease which
requires treatment. As the diagnosis of PCa based on PSA levels
and the DRE alone is not reliable, confirmation using other
approaches such as invasive biopsies and/or MRI scans
is required.
Traditionally, PCa has been diagnosed by performing
transrectal ultrasound (TRUS) guided prostate biopsies.
However, such a biopsy technique has a cancer detection rate
of less than 30% in a benign feeling prostate. The major
drawback in performing TRUS prostate biopsies is that it is
only possible to accurately biopsy the posterior peripheral and
transition zone due to limitations in mobility of the ultrasound
probe. Currently, ~55% of transrectal ultrasound (TRUS)
biopsies return negative results (5). A negative TRUS biopsy of
the prostate does not therefore necessarily equate to a cancer-free
prostate, as prostate cancer may be present in the anterior parts
of the peripheral or transition zone that are inaccessible via such
a route. As such, a negative TRUS biopsy could falsely be
reassuring to the patient who then subsequently presents later
with advanced/metastatic PCa. As the rectum is highly colonized
with bacteria, approximately 3-5% of men who undergo TRUS
guided prostate biopsies will experience potentially life
threatening urosepsis (6) with many such patients requiring
ITU care. Worryingly, the risk of developing urosepsis has
increased over the past decade due to the development of
multi-drug resistant fecal bacteria (7). Another issue is that the
PCa detection rate significantly reduces when TRUS biopsies are
repeated due to rising PSA (8).
The diagnostic strength of an alternative biopsy approach -
the transperineal template prostate (TPTP) biopsy - which
involves interrogating the entire prostate using a grid/template
of needles inserted via the perineal skin has been shown toDecember 2021 | Volume 12 | Article 786828
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(52%-68%) (9). Directly comparing TRUS against TPTP in
biopsy naïve men has also revealed TPTP to significantly
outperform TRUS with respect to the detection of PCa (60%
versus 32%) (10). Although MRI-based diagnosis of PCa is
continuing to develop, MRI cannot currently be used as a sole
diagnostic to replace biopsies, as a positive MRI can be incorrect
in ~25% of cases and a negative MRI incorrect in ~20% of cases.
MRI can be used on patients with a PSA of 10-20 ng/ml and
~70% of these men are currently having `up front’ MRI which
consumes vital healthcare resources. However, MRI does have
clinical utility for staging and focusing of biopsies. It is therefore
essential that misdiagnosis and unnecessary procedures are
reduced by the development of non-invasive approaches such
as blood tests/liquid biopsies that are more accurate at detecting
and categorizing the clinical risk of PCa than the PSA test.
Given the reciprocal relationship between cancer and a
patient’s immune system, we proposed, and have previously
shown, that the presence of PCa is reflected by detectable
changes in the peripheral blood immunome. We were the first
to successfully use computational modelling of multi-parametric
flow cytometry data of peripheral blood T and B cells to identify
phenotypic profiles (‘signatures’) which, when input into a
computational machine learning tool, reliably identifies the
presence of PCa in asymptomatic men with PSA levels <20 ng/
ml (11). Managing this group of individuals presents a particularly
significant clinical quandary, because although only 30%-40% of
these men will have PCa, currently all must undergo potentially
unnecessary invasive prostate biopsies. For this study (11) we
devised a combinatorial feature selection method to identify a
unique peripheral blood immune cell phenotypic profile
(`signature’) of five T and B cell phenotypic ‘features’ which was
incorporated into an interpretable machine learning model. Our
approach achieved 83% accuracy, versus 77.78% for the PSA test,
and decreased false positives by 12.9% (11).
Using samples from the same cohort of asymptomatic men
having PSA levels <20 ng/ml, we subsequently demonstrated that
incorporating eight peripheral blood natural killer (NK) cell
phenotypic features into an Ensemble machine learning
prediction model could also distinguish between the presence of
benign prostate disease and PCa. Furthermore, and very
importantly, we could also demonstrate that the machine learning
model,whenadapted to incorporate 32NKcell phenotypic features,
could predict the D’Amico Risk Classification (clinical risk of PCa)
in those patients identified as having PCa and was thereby able to
accurately differentiate between the presence of low-/intermediate-
risk disease and high-risk disease without the need for additional
clinical data (12). These studies usedGeneticAlgorithms to identify
combinations of phenotypic features which were used to develop
prediction models based on the k-Nearest Neighbour (kNN)
classification algorithm and Ensemble machine learning
prediction models (11, 12).
The phenotypic datasets utilised in our previous studies were
generated from asymptomatic men who had PSA levels <20 ng/ml
and who had all undergone diagnosis using the more definitive
TPTP biopsy (11, 12). The aim of the study presented herein is toFrontiers in Immunology | www.frontiersin.org 3extend thefindingsofourprevious studies todeterminewhether the
T and B cell phenotypic features which have previously been
identified as being able to distinguish between benign prostate
disease andPCa inasymptomaticmenhavingPSA levels< 20ng/ml
(11) canalsobeused todetect thepresenceandclinical riskofPCa in
a larger cohort of patients whose PSA levels ranged between 3 and
2617 ng/ml, the PCa disease status of whom had been determined
using either the TPTP or TRUS biopsy. For this, we implemented
two separate bidirectional Long Short-TermMemory Deep Neural
Network (biLSTM)models, one for predicting the presence of PCa
and another for predicting the clinical risk of any PCa present, as
defined by the D’Amico Risk Classification. Given limited sample
numbers, it was not possible to undertake a similar analysis using
the NK cell phenotyping dataset from our previous study (12).MATERIALS AND METHODS
Sample Collection
Peripheral blood samples were obtained from asymptomatic
men suspected of having PCa that attended the Urology Clinic
at Leicester General Hospital (Leicester, UK) between 24 October
2012 and 15 August 2014. Samples were obtained from two
cohorts of patients, termed the ‘TPTP’ and ‘TRUS’ cohorts (see
below for more details). For both cohorts, patients were recruited
and treated as described previously (10).
Data Collection
Phenotypic data were generated from a total of 130 males (42
diagnosed with benign disease and 88 diagnosed with cancer, as
confirmed by TPTP or TRUS biopsy evidence) (Tables 1, 2). Of
the 42 subjects diagnosed with benign disease; 2 were diagnosed
with Atypical Small Acinar Proliferation (ASAP). 11 with Atypia,
13 with High Grade Prostatic Intraepithelial Neoplasia (PIN)
and 16 with benign disease. Of the men diagnosed with PCa, 18
had low-risk, 44 had intermediate-risk, and 25 had high-risk
cancer based on their D’Amico Risk Classification for Prostate
Cancer (13). The D’Amico Risk for one patient was not available
as no Gleason score values were provided. Further details
regarding the TRUS (14) and TPTP (9, 10) biopsy techniques
have been provided elsewhere.
Some of the data used in the present study have been
previously published (11). These data were derived from 72
males having PSA levels < 20 ng/ml who had a TRUS and then a
TPTP biopsy (11). The mean age for this cohort was 66 years old
(age range of 50–84 years old).
Flow Cytometric Analysis
Peripheral blood was collected from all individuals using
standard clinical procedures, aliquots of which (30 ml) were
transferred into sterile 50 ml polypropylene (Falcon) tubes
containing 300 μl sterilised Lithium Heparin (1000 U/ml,
Merck Millipore). Anti-coagulated samples were immediately
transferred to the John van Geest Cancer Research Centre at
Nottingham Trent University (Nottingham, UK) and processed
immediately upon receipt (always within 3 hours of collection).December 2021 | Volume 12 | Article 786828
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the inclusion of BD Trucount™ beads (BD Biosciences; Mountain
View, CA, USA), as per the manufacturer’s protocol. For the flow
cytometric analysis, 100 ml of blood was mixed directly in the BD
Trucount™ bead tube and T cell, B cell, and NK cell populationsFrontiers in Immunology | www.frontiersin.org 4identified using the conjugated monoclonal antibodies (mAbs)
detailed in Table 3. Samples were incubated for 15 min at room
temperature, protected fromthe light, afterwhich erythrocyteswere
lysed by incubating samples for 15min at room temperature in BD
Pharm Lyse™ (BD Biosciences). Once staining was complete, cellsTABLE 1 | Clinical demographics of cohorts.
No. of Patients Min. Age Max. Age Mean Age SD. Age Min. PSA Max. PSA Mean PSA SD. PSA
Total: Benign 42 51 77 65.88 5.76 4.70 19.00 8.43 3.33
ASAP 2 60 61 60.50 0.50 5.30 7.80 6.55 1.25
Atypia 11 51 77 64.73 7.19 4.70 19.00 8.23 3.71
High PIN 13 54 75 64.46 5.93 5.10 12.00 7.82 2.27
Benign 16 63 5.3 68.50 3.16 5.30 18.00 9.29 3.70
Total Cancer: 88 52 88 69.88 7.97 3.00 2617.00 51.00 277.41
Low 18 55 78 65.33 5.92 4.70 9.80 6.55 1.55
Intermediate 44 53 88 69.75 8.04 3.00 19.00 9.56 3.49
High 25 52 88 73.36 7.59 4.30 2617.00 157.10 505.11
Unknown 1 70 19.00December 2021 | Volume 12 | ArticTABLE 2 | Clinical demographics of TRUS and TPTP biopsy cohorts.
TRUS Biopsy Cohort
TRUS Gleason grade TRUS Gleason score Number of patients Group Age Range (yr) Group PSA range (ng/ml) Clinical RIsk
Benign Benign 6 63-75 5.5-18 –
High PIN 3 60-69 6.9-12 –
Atypia 2 54-67 4.9-5.6 –
Gleason 6 3+3 13 55-88 3.9-19 Low-Intermediate
Gleason 7 3+4 10 52-86 3-76 Intermediate - High
4+3 8 63-85 7.8-248 Intermediate - High
Gleason 8 4+4 2 70-74 7.9-12 High
Gleason 9 4+5 9 67-88 4.3-2617 High
5+4 2 69-84 40-118 High
Unknown Cancer 1 74 75 High
Small cell Cancer 2 66-80 59-83 High
TPTP Biopsy Cohort
TPTP Gleason Grade TPTP Gleason score Number of patients Group Age range (yr) Group PSA range (ng/ml) Stage
Benign Benign 10 65-71 5.3-15 –
High PIN 10 54-71 5.1-12 –
ASAP 2 60-61 5-3-7.8 –
Atypia 9 51-77 4.7-19 –
Gleason 6 3+3 16 56-85 4.7-11 Low-Intermediate
Gleason 7 3+4 18 53-79 4.7-13 Intermediate
4+3 5 55-81 5.1-19 Intermediate
Gleason 9 4+5 2 70-75 6.3-18 IntermediateTABLE 3 | Monoclonal antibody (mAb) panel for B and T cell phenotyping.
Antibody Fluorochrome Clone Supplier
CD8 FITC SK1 BioLegend
CD19 PE HIB19 BioLegend
CD28 PE-Texas Red (ECD) CD28.2 Beckman Coulter
CD56 PE-Cy5™ NCAM BioLegend
CD3 PE-Cy7™ HIT3a BioLegend
CD45RA Allophycocyanin (APC) HI100 eBioscience
CD14 Alexa Fluor™ 700 HCD14 BioLegend
CD27 APC eFluor™ 780 O323 eBioscience
CD45 Pacific Blue™ J33 Beckman Coulter
CD4 Krome Orange 13B8.2 Beckman Coulterle 786828
Cosma et al. Identifying Prostate Cancer Using Immunophenotypingwere washed in phosphate buffered saline (PBS), resuspended in
Coulter Isoton™ diluent. Data were acquiredwithin 1 h using a 10-
color/3-laser Beckman Coulter Gallios™ flow cytometer and
analyzed using Kaluza™ v1.3 data acquisition and analysis
software (Beckman Coulter). Controls used a “Fluorescence
minus One”, “FMO” approach (15). A typical gating strategy for
the analyses is presented in Figure 1.Deep Neural Networks for Predicting the
Presence of PCa and Its Clinical Risk
(biLSTM)
The bidirectional Long Short-TermMemoryDeepNeuralNetwork
(biLSTM) is also known as a bidirectional Recurrent Neural
Network (RNN). LSTM is an artificial recurrent neural network
architecture used in the field of deep learning. Unlike the standard
feedforward neural network, the LSTM has feedback connectionsFrontiers in Immunology | www.frontiersin.org 5which enable it to process entire sequences of data. A biLSTM is a
type of LSTM with a bidirectional layer and learns bidirectional
long-term dependencies in sequence data. The architecture of the
proposed biLSTM for detecting the presence of PCa is shown in
Table 4. Although the biLSTM is widely applied to sequential data,
it has been, and can also be successfully applied to non-
sequential data.
A biLSTM model learns the input sequence both forward and
backwards and concatenates both interpretations. The model
duplicates the first recurrent layer in the network and creates two
side-by-side layers, then provides the input sequence ‘as-is’ as
input to the first layer and providing a reversed copy of the input
sequence to the second (16). The training data are shuffled before
each training epoch, and the validation data are shuffled before
each network validation. Given that the mini-batch size does not
evenly divide the number of training samples, the network
discards the training data that do not fit into the finalFIGURE 1 | Representative gating strategies for the flow cytometric analysis of single cells. The staining panel confirmed CD45 expression then determined cell
populations as CD14+ monocytes, CD3-CD56+ NK cells (with CD56bright and CD56dim subsets), CD3+CD56+ NKT cell subpopulations, CD19+ B cells, CD3+CD4+
and CD3+CD8+ Naïve, Central Memory, Effector Memory, Terminally Differentiated Effector Memory Cells Expressing CD45RA T cell populations. The definition of
monocytes based on CD45+CD4+ generated the same data as defining them based on CD3-CD14+ (data not shown).December 2021 | Volume 12 | Article 786828
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mentioned above avoids discarding the same data at every epoch.
Two biLSTM models were implemented. The first biLSTM
model takes as input immunophenotypic features and clinical
data and is trained to detect the presence of PCa. The second
model takes as input a set of biomarkers comprising
immunophenotypic features and clinical data and is trained to
predict the clinical risk the PCa when PCA has been identified as
being present.
The models were built using combinations of phenotypic
features and clinical data to determine the best combinations for
training each model. Figure 2 shows how prediction models for
detecting the presence of PCA and its clinical risk can be utilised
to assist clinical diagnosis.
Methodology for Evaluating the Deep
Neural Network Models
The dataset was initially split into datasets derived from men
with benign prostate disease and patients with PCa, and each of
these datasets was randomly split into ‘train’, ‘validation’ andFrontiers in Immunology | www.frontiersin.org 6‘test’ datasets with a split ratio of 60:20:20, respectively. This
random split process was repeated 30 times to create 30 different
train, validation and testing sets. This allowed for exhaustive
evaluations to be carried out using different sub-populations of
the dataset for train, validation, and test purposes. The biLSTM
Deep Neural Network models utilised the train sets for training,
and the validation sets were utilised during the training process
to improve the models’ learning. The test sets are unseen during
training, and therefore the test results can be considered to
represent mini clinical trials. The results at the end of the 30
runs were collected and analyzed. The methodology for
evaluating the Deep Learning models is illustrated in Figure 3.
Performance Evaluation Measures
A set of relevant metrics were adopted for evaluating the
performance of the proposed biLSTM models, These were built
using six different ‘feature’ sets: FC; PSA; FC+PSA; FC+Age;
FC+Age+PSA; Age+PSA. ‘FC’ stands for flow cytometry features
and comprises five phenotypic features CD8+CD45RA-CD27-
CD28- (CD8+ Effector Memory cells), CD4+CD45RA-CD27-CD28-
(CD4+ Effector Memory cells), CD4+CD45RA+CD27-CD28- (CD4+
Terminally Differentiated Effector Memory Cells re-expressing
CD45RA), CD3-CD19+ (B cells), CD3+CD56+CD8+CD4+ (NKT
cells), as identified previously as being able to discriminate
between benign prostate disease and PCa (11).
Let model PCaPresence be a model for detecting the presence
of PCa, and PCaRisk be a model for predicting whether a patient
with PCa has D’Amico high-risk (H-risk) or low/intermediate
risk (LI-risk) disease.
• |TP| stands for True Positive. |TP| in a PCaPresence model is
the total number of patients diagnosed with PCa who were
correctly classified with PCa. |TP| in a PCaRisk model is the
total number of patients diagnosed with H-risk PCa who were
correctly classified with H-risk PCa.FIGURE 2 | Flow chart illustrating the process to detect the presence of PCa and its clinical significance. Stage 1 (Model 1): distinguishes between men with benign
prostate disease and PCa; Stage 2 (Model 2): predicts risk (in terms of clinical significance) in men identified as having PCa in Stage 1. Note that Stage 1 can also
detect PCa in men with PSA levels < 20 ng/ml.TABLE 4 | Parameter settings of the Deep Learning Models.
maxEpochs 20
miniBatchSize 10
Initial learning rate 0.01
Shuffle Every epoch
BiLSTM layers
Sequence Input Sequence input with n dimensions, where n is the number
of features
BiLSTM BiLSTM with 256 hidden units
Fully Connected 2 fully connected layer
Fully Connected 3 fully connected layer
Softmax Softmax
Classification Output crossentropyex
Solver Stochastic gradient descent with momentum
(SGDM) optimizerDecember 2021 | Volume 12 | Article 786828
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the total the number of patients with benign disease who were
correctly classified with benign disease. |TN| in a PCaRisk
model is the total the number of LI-risk patients who were
correctly classified as LI-risk.
• |FP| stands for False Positive. |FP| in a PCaPresence model is
the total number of patients with benign disease who were
incorrectly classified with PCa. |FP| in a PCaRisk model is the
total number of LI-risk patients who were incorrectly
classified as H-risk.
• |FN| stands for False Negative. |FN| in a PCaPresencemodel is
the total number of patients with PCa who were incorrectly
classified with benign disease. |FN| in a PCaRisk model is the
total number of H-risk patients who were incorrectly
classified as LI-risk.
• |P| stands for Positive. |P| in a PCaPresence model is the total
number of patients with PCa that exist in the dataset. |P| in a
PCaRisk model is the total number of H-risk patients that
exist in the dataset. |P|=|TP|+|FN|.
• |N| stands for Negative. |N| in a PCaPresence model is the
total number of patients with benign disease that exist in the
dataset. |N| in a PCaRisk model is the total number of LI-risk
patients that exist in the dataset. |N|=|FP|+|TN|. The
following commonly used evaluation measures can be
defined.
Accuracy =
TPj j + TNj j
TPj j + FPj j + FNj j + TNj j , ϵ ½0, 1 (1)
Sensitivity =
TPj j + TNj j
TPj j + FNj j , ϵ ½0, 1 (2)Frontiers in Immunology | www.frontiersin.org 7Sensitivity is also known as the True Positive Rate (TRP).
Specificity =
TNj j
TNj j + FPj j , ϵ ½0, 1 (3)
Specificity is also known as the True Negative Rate (TNR).
FPR =
FPj j
FPj j + TNj j = 1 − Specificity, ϵ ½0, 1 (4)
FPR stands for False Positive Rate.
The closer the values of Accuracy, Sensitivity (i.e. TPR,
Sensitivity) and Specificity (i.e. TNR, Specificity) are to 100%,
then the better the performance of a model.
The Receiver Operating Characteristic (ROC) evaluates the
quality of a prediction model’s performance. The ROC curve has
an optimal ROC point which comprises two values: the FPR and
the TPR values. The optimal ROC point is computed by function
(6) for finding the slope, S.
S =
Cost(PnN) − Cost(NnN)




where, in a PCaPresence detection model let the positive class
be the class containing patients with PCa, and the negative class
be the class containing men having benign prostate disease. In
the PCaRisk prediction model let the positive class be the H-risk
group and the negative class be class containing the records of
the patients belonging to the low and intermediate class (LI-risk).
(N|P) is the cost of misclassifying a positive class as a negative
class; and Cost (P|N) is the cost of misclassifying a negative class,
as a positive class.FIGURE 3 | Experimental methodology for evaluating the Deep Learning Models.December 2021 | Volume 12 | Article 786828
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line with slope S from the upper left corner of the ROC plot
(FPR=0%, TPR=100%) down and to the right until it intersects
the ROC curve. The Area Under the ROC Curve (AUC) is
another important performance evaluation metric which reflects
the capacity of a model to discriminate between the data
obtained from individuals with benign prostate disease and
patients with PCa. The larger the AUC, the better the overall
capacity of the classification system to correctly distinguish
between benign disease and PCa.Pre-Processing of Dataset
The dataset comprised 7 features, 5 of which were peripheral
blood flow cytometric T and B cell phenotyping features identified
in our previous study (11) and the remaining two of which were
the clinical features PSA level and Age. The five phenotypic
features were: CD8+CD45RA-CD27-CD28- (CD8+ Effector
Memory cells), CD4+CD45RA-CD27-CD28- (CD4+ Effector
Memory cells), CD4+CD45RA+CD27-CD28- (CD4+ Terminally
Differentiated Effector Memory Cells re-expressing CD45RA),
CD3-CD19+ (B cells), CD3+CD56+CD8+CD4+ (NKT cells). The
data for each immune phenotyping feature were standardized
using z-score transformation. The standardized z-scores are scores
(or data values) that have been given a common standard. This
standard is a mean of zero and a standard deviation of 1. The PSA
and Age values were not standardized (Table 5).
The Kolmogorov-Smirnov and Shapiro-Wilk statistical tests
demonstrated that the data are not normally distributed and non-
parametric tests were therefore used for the analyses (Table 6).Frontiers in Immunology | www.frontiersin.org 8RESULTS
Differences in Measured Features
Between Men With Benign Prostate
Disease and Patients With PCa
The Mann-Whitney U test revealed that there are no significant
differences (p<0.05) between the groups for the flow cytometry
features, but that the age and PSA levels in men with benign
disease and those with PCa were different (p<0.05, Table 7).
Given that there are 7 comparisons, the Bonferroni correction
was applied and the a value was set to a= 0.007 to reduce Type I
error. Using the adjusted a value revealed that there were no
significant differences between the values of the features of the
benign and PCa groups.
Table 7 also reports the effect size which is the magnitude of the
difference between groups, and it is computed using r=Z√N, where
Z is the output of the Mann-Whitney U Test, and N is the total
number of samples. According toCohen (17), the effect size is low if
the value of r varies around 0.1, medium if r varies around 0.3, and
large if r varies more than 0.5. This means that if the values of two
groups do not differ by 0.2 standard deviations or more, then the
difference is trivial, even if it is statistically significant. Hence, it can
be concluded that there are no statistically significant differences
between the features indicated in Table 7 in the benign prostate
disease and PCa groups, and that any differences that do exist are
small and trivial.
The nonparametric Spearman’s rank-order correlation shows
there to be no strong positive or strong negative correlations
amongst the outputs which will be utilised to build the machine
learning classifier (Figure 4).TABLE 6 | Tests for normal distribution in data.
Kolmogorov-Smirnovaa Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
CD8+CD45RA-CD27-CD28- 0.297 130 0.000 0.526 130 0.000
CD4+CD45RA-CD27-CD28- 0.311 130 0.000 0.509 130 0.000
CD4+CD45RA+CD27-CD28- 0.346 130 0.000 0.431 130 0.000
CD3-CD19+ 0.195 130 0.000 0.560 130 0.000
CD3+CD56+CD8+CD4+ 0.354 130 0.000 0.299 130 0.000
PSA 0.441 130 0.000 0.104 130 0.000
Age 0.098 130 0.004 0.979 130 0.037December 2021 | Volume 12 | Article 7a. Lilliefors Significance Correction.
Kolmogorov-Smirnov statistic with a Lilliefors significance level for testing normality, and the Shapiro-Wilk statistic. All features have a Sig. value p<0.05 and thus are not normally
distributed. For this reason, non-parametric tests were used.TABLE 5 | Dataset statistics.
Benign Prostate Disease Prostate Cancer
Min Max Mean SD Min Max Mean SD
CD8+CD45RA-CD27-CD28- -0.53 6.02 -0.11 1.01 -0.53 6.02 0.05 0.99
CD4+CD45RA-CD27-CD28- -0.49 4.74 0.10 1.07 -0.49 6.19 -0.05 0.97
CD4+CD45RA+CD27-CD28- -0.40 4.22 0.05 1.00 -0.40 6.02 -0.03 1.00
CD3-CD19+ -1.03 8.94 0.22 1.50 -0.94 3.10 -0.11 0.62
CD3+CD56+CD8+CD4+ -0.37 3.82 0.01 0.68 -0.36 9.93 0.00 1.12
PSA 4.7 19 8.43 3.37 3 2617 51.00 279
Age 51 77 65.88 5.83 52 88 69.88 8.0286828
Cosma et al. Identifying Prostate Cancer Using ImmunophenotypingTPTP vs TRUS: Differences in
Patient Profiles
TPTP is significantly better at diagnosing PCa than TRUS
biopsies in biopsy naïve men with an elevated PSA <20 ng/ml
and a benign feeling prostate (10). Nafie et al. have therefore
proposed that TPTP should be regarded as the biopsy technique
of choice in such cases (10).
The Kruskal-Wallis H test is an extension of the Mann-
Whitney U test, is the nonparametric equivalent of the one-way
analysis of variance and detects differences in distribution
location. The major difference between the Mann-Whitney U
and the Kruskal-Wallis H is simply that the latter can
accommodate more than two groups. Both tests require
independent (between-subjects) designs and use summed rank
scores to determine the results. Therefore, for the analysis in this
subsection the Kruskal-Wallis H test was suitable. The Kruskal-
Wallis H (also known as the ‘one-way ANOVA on ranks’)
rank-based nonparametric test, was used to determine whether
there are any statistically significant differences between theFrontiers in Immunology | www.frontiersin.org 9immunophenotypic profiles of the patients when grouped based
on biopsy methods and diagnosis. Therefore, a new variable was
created, BiopsyDiagnosis, where the biopsy type (i.e. TPTP or
TRUS) and diagnosis (i.e. benign prostate disease or PCa) were
merged into a four separate labels: TPTPBenign, TRUSBenign,
TPTPCancer, TRUSCancer, and the Kruskal-Wallis test was
applied to determine significant difference between the
TPTPBenign and TRUSBenign groups, and between
the TPTPCancer and TRUSCancer patient groups. Table 8 shows
the characteristics of each group of subjects and Table 9 the results
of the Kruskal-Wallis H test which was applied to determine
differences between the ranks of the abovementioned groups.
The a level for these tests was set to 0.005, however applying a
Bonferroni correction which was applied to reduce the chance of
a false positive (i.e. a Type I error) reduced the a value to 0.05
since there exist 10 possible comparisons. As shown in Table 9,
the absence of any significant differences (Asymp. Sig) between
any of the immunophenotyping features of the TPTPBenign and
TRUSBenign patients is a good indicator that data collectedTABLE 7 | Statistical tests for checking on significant differences between groups.
Mann-Whitney U Wilcoxon W Z Asympt. Sig (2-tailed) Effect sizer=Z√N
CD8+CD45RA-CD27-CD28- 1700.5 2603.5 -0.734 0.463 0.064 (small)
CD4+CD45RA-CD27-CD28- 1614.5 5530.5 -1.162 0.245 0.102 (small)
CD4+CD45RA+CD27-CD28- 1559.5 5475.5 -1.436 0.151 0.126 (small)
CD3-CD19+ 1598.0 5514.0 -1.245 0.213 0.109 (small)
CD3+CD56+CD8+CD4+ 1562.0 5478.0 -1.424 0.154 0.125 (small)
PSA 1302.5 2205.5 -2.717 0.007 0.238 (small)
Age 1344.0 2247.0 -2.515 0.012 0.221 (small)December 2021 | Volume 1The alpha value has been set to alpha = 0.007 after the Bonferroni correction. This means that there are no significant differences in the mean values for the benign prostate disease and
PCa groups since none of the p values are less than 0.007. The effect size, r values, show that differences between the groups are small and any differences between the benign prostate
disease and PCa groups are trivial.FIGURE 4 | Heatmap of flow cytometry and other features. Each cell of the heatmap provides a Spearman rho correlation value between two features. There are no
strong positive or strong negative correlations amongst the inputs.2 | Article 786828
Cosma et al. Identifying Prostate Cancer Using Immunophenotypingduring TPTP and TRUS biopsy can be combined when training a
machine learning model.
Results of the Deep Learning Models for
Identifying the Presence of PCa
The performance of various biLSTM Deep Neural Network
models (whose architecture is described above) for predicting
the presence of PCa when using six different subsets of features
was assessed. Table 10 shows the training, validation, and test
results of the models. Table 10 shows that the FC+Age was the
best model, achieving an accuracy of 86.92% on the validationFrontiers in Immunology | www.frontiersin.org 10set, and 86.79% on the test set. More specifically, the model was
able to detect the presence of PCa in the validation set with Acc:
86.92% (± 0.10), Sensitivity: 83.70% (± 0.16); Specificity: 94.17%
(± 0.11); AUC: 88.94% (± 0.07), ORP-FPR: 9.17% (± 0.20), ORP-
TPR: 85.74% (± 0.14) (Table 10). Results from the test set (set
not used during training or validation) were Acc: 86.79% (±
0.10), Sensitivity: 82.78% (± 0.15); Specificity: 95.83% (± 0.11);
AUC: 89.31% (± 0.07), ORP-FPR: 7.50% (± 0.20), ORP-TPR:
84.44% (± 0.14).
The validation results for predicting the presence of PCa
using PSA revealed a 27.91% lower ORP-FPR when combiningTABLE 8 | Patients by biopsy group.
Frequency % Valid % Cumulative %
TPTPBenign 31 23.8 23.8 23.8
TRUSBenign 11 8.5 8.5 32.3
TPTPCancer 41 31.5 31.5 63.8
TRUSCancer 47 36.2 36.2 100.0
Total 130 100 100December 2021 | Volume 12TABLE 9 | Statistical tests for checking on significant differences between biopsy groups and diagnosis.
Kruskal-Wallis H df Asymp. Sig.
TPTP Benign vs TRUS Benign
CD8+CD45RA-CD27-CD28- 0.005 1 0.943
CD4+CD45RA-CD27-CD28- 0.000 1 1.000
CD4+CD45RA+CD27-CD28- 0.005 1 0.943
CD3-CD19+ 3.511 1 0.061
CD3+CD56+CD8+CD4+ 0.001 1 0.977
TPTP Cancer vs TRUS Cancer
CD8+CD45RA-CD27-CD28- 2.267 1 0.132
CD4+CD45RA-CD27-CD28- 3.086 1 0.079
CD4+CD45RA+CD27-CD28- 0.373 1 0.541
CD3-CD19+ 5.196 1 0.023
CD3+CD56+CD8+CD4+ 0.039 1 0.844| AKruskal-Wallis Test.
Grouping variable BiopsyDiagnosis.TABLE 10 | Results of the biLSTM Deep Neural Network models for predicting the presence of PCa.
BILSTM Training Validation Results (Mean ± SD) Test Results (Mean ± SD)
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Cosma et al. Identifying Prostate Cancer Using ImmunophenotypingFC+PSA than when using PSA alone. For the test results, the
ORP-FPR was 20.83% lower when combining FC+PSA than
when using PSA alone. The standard deviation values of the
FC+PSA were lower indicating a more stable model.
The Role of Age and Its Impact on
Predicting the Presence of PCa
Combining Age with immunophenotypic features improved
prediction accuracy and therefore age appears to be a good
predictor for the presence of PCa when combined with the flow
cytometry phenotypic features. As the correlation chart in Figure 4
shows there to be no strong positive or strong negative correlations
between age and the rest of the features including diagnosis, we can
rule out the fact that correlation is biasing the models’ predictions
(i.e. since there are no strongpositive or strongnegative correlations
betweenAge and thepresenceofPCa).However, a further statistical
investigation was used to conclude whether age is biasing the
performance of the prediction models. The two-sample
Kolmogorov-Smirnov test, a nonparametric hypothesis test was
applied for testing if the variable age has identical distributions in
the two populations (i.e. the benign prostate disease and PCa
groups). **Note that this is different to the results shown in
Table 6 which checks whether the variables are normally
distributed, and not whether the two groups follow the same
distributions. Figure 5 shows the distribution of Age values across
the benign prostate disease and PCa groups.**
The a value was set to 0.01 to minimize Type I error. The test
returned p=0.033, Z=1.431 (and p>0.01) meaning that samples
from the benign prostate disease and PCa groups are from the
same continuous distribution at the 1% significance level. TheFIGURE 5 | Age of men with benign prostate disease and patients with prostate can
Frontiers in Immunology | www.frontiersin.org 11next step was to determine whether there are any significant
differences in the mean age ranks of these two groups that could
be biasing the prediction. The a value was again set to 0.01 to
prevent Type I errors and make it harder to predict significant
differences. As the Mann-Whitney test revealed p=0.012, Z=-
2.515 we can assume that there are no significant differences in
the mean ranks of age at the 1% significance level.
However, to further ensure the correct conclusions are reached,
the Moses Test of extreme reaction was carried out to recompute
the differences between groups when the extreme outliers are not
considered. The test is a distribution-free non-parametric test of
the difference between two independent groups in the extremity
scores (in both directions) that the groups contain. For the benign
prostate disease and PCa groups, Moses tests whether extreme
values are equally likely in both populations, or if they are more
likely to occur in the population from which the sample with the
larger range was drawn. The scores from the benign prostate
disease and PCa groups are pooled and converted to ranks, and
the test statistic is the span of scores (computed as the range
plus 1) in one of the groups chosen arbitrarily. An exact
probability is computed for the span and then recomputed after
dropping a specified number of extreme scores from each end of
its range. The exact one-tailed probability is calculated. After
trimming the entire dataset, there were 5 patients ≤54 years old
and 6 patients ≥84 years old. The information for the Moses
extreme reaction test shows that the benign prostate disease and
PCa groups have different age values with a Sig. = 0.006. However,
when removing the extreme outliers, the Sig. value increases to
Sig. = 0.082 hence the two groups have similar age values when the
extreme outliers are removed.cer (PCa).
December 2021 | Volume 12 | Article 786828
Cosma et al. Identifying Prostate Cancer Using ImmunophenotypingRevisiting the results in Table 7, and based on the observations
described in this section, we can conclude that the algorithms are
not biased towards age, and that age in combination with the
immunophenotypic features forms a good predictor for the
presence of PCa. It is important to mention that if age was biasing
the output of the prediction model, then other machine learning
models (FC+Age+PSA, Age+PSA) would have consistently
delivered high prediction results, because machine learning
models excel at detecting patterns in data and would have found
the association (pattern) between the Age and the output variable
(diagnosis) if this had existed. Based on these observations, it can be
concluded that age isnot biasing the outputof the predictionmodel.
Results of the Deep Learning Models for
Predicting the Clinical Risk of PCa
Men diagnosed with low-risk or small volume intermediate-risk
PCa will very rarely require treatment compared to men who have
been diagnosed with high-risk PCa. It is therefore important to
detectmen in theH-risk group accurately toprioritise treatment for
those men, and to prevent unnecessary invasive procedures.
Consequently, we determined whether biLSTM models can
differentiate between the clinical risk of PCa using the same
features as those which have been used for building the models
for predicting the presence of PCa (Table 11). Given that there
are 85 patients having low-risk (n=18), intermediate-risk (n=44)
or high-risk (n=25) PCa, patients were grouped into L/I (low-
intermediate) and H (high) risk groups. The biLSTM model that
was designed for predicting risk was then utilised to predict risk
(L/I or H). The test results in Table 11 show that the model
which combined the flow cytometry features with PSA was able
to predict clinical risk in the validation set with Acc: 94.51% (±
6.35), Sensitivity: 92% (± 21.09); Specificity: 95.56% (± 2.99);
AUC: 93.78% (± 10.50), ORP-FPR: 4.44% (± 2.99), ORP-TPR:
92% (± 21.09). The results on the test set with Acc: 94.90% (±
6.29), Sensitivity: 92% (± 21.39); Specificity: 96.11% (± 0.00);
AUC: 94.06% (± 10.69), ORP-FPR: 3.89% (± 0.00), ORP-TPR:
92% (± 21.39). These are a positive indicator, and it is expectedFrontiers in Immunology | www.frontiersin.org 12that with a larger dataset the model will be able to learn better,
and the standard deviation values will reduce. Comparing the
results of the FC+PSA model with those which uses PSA values
alone, the FCA+PSA model returned better validation and test
results. It therefore appears that PSA is a good predictor of
clinical risk when combined with FC values.
Experimental results described above using models for
detecting the presence of PCa found that Age is a feature
which, when combined with the immunophenotypic profiling,
delivers a greater predictive accuracy than when it is used alone.
Here, we follow a similar analysis for interrogating the impact of
PSA. As indicated in the correlation chart (Figure 4), there are
no strong positive or strong negative correlations between PSA
and the other features.
The two-sampleKolmogorov-Smirnov testwas applied to check
for identical distributions in the two populations (i.e. benign
prostate disease and PCa). The test returned p=0.033, Z=1.431
(and p>0.01) meaning that samples from the benign prostate
disease and the PCa groups are of the same continuous
distribution at the 1% significance level. Next, we determined
whether significant differences in the mean ranks of the benign
prostate disease and PCa groups could be biasing the prediction.
The alpha value was set to 0.01 to prevent Type I errors andmake it
harder to predict significant differences. The Mann-Whitney test
returnedp=0.007, Z=-2.717. Therefore, it can be assumed that there
are significant differences in the mean ranks of age at the 1%
significance level. These results show that the PSA could be
influencing the risk of disease, which makes clinical sense given
that the high-risk patients often (but not always) have higher PSA
values than the low and intermediate-risk patients (Table 11).DISCUSSION
It is essential that men with low-risk prostate abnormalities are
not diagnosed with PCa, as those with low-grade disease do not
require active treatment, yet they become `labelled’ as havingTABLE 11 | Results of the biLSTM deep neural network models for predicting the D’Amico risk of PCa.
BILSTM Training Validation Results (Mean ± SD) Test Results (Mean ± SD)
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Cosma et al. Identifying Prostate Cancer Using ImmunophenotypingPCa. This can have adverse psychological and financial
consequences and assign these men to life-long surveillance.
Inappropriate assignment of men to potentially life-threatening
invasive procedures and lifelong surveillance for PCa has
significant psychological, quality of life, financial and societal
consequences. Although the diagnosis of PCa based on PSA
levels alone is not reliable, combining PSA measurements with
other approaches might strengthen the diagnostic value of PSA
measurements and identifying its clinical risk, and it is based on
this concept that the current study has been performed.
Given the established reciprocal relationship(s) between cancers
and the immune system,wehave previouslydemonstrated (11) that
a set of five phenotypic features (CD8+CD45RA-CD27-CD28-
(CD8+ Effector Memory cells), CD4+CD45RA-CD27-CD28- (CD4+
Effector Memory cells), CD4+CD45RA+CD27-CD28- (CD4+
Terminally Differentiated Effector Memory Cells re-expressing
CD45RA), CD3-CD19+ (B cells), CD3+CD56+CD8+CD4+(NKT
cells) could be used to identify the presence of PCa in a
population of asymptomatic men with PSA levels that were
elevated above the normal, but <20 ng/ml (‘normal’ is ~5 ng/ml),
a population which presents a significant clinical challenge. In a
subsequent study we identified an NK cell phenotypic signature
which can be used to identify both the presence and clinical risk of
PCa in the same cohort of asymptomatic men (12).
Herein, we explored whether this T and B cell phenotypic
signature can be incorporated into models that can predict the
presence and clinical risk of PCa in men having elevated PSA
values of any level, and whose disease status had been defined
using the TRUS and TPTP biopsy. Given limited sample
numbers, it was not possible to undertake a similar analysis
using the NK cell phenotyping dataset. For this, we built two
prediction models: the first to detect the presence of PCa and the
second to predict the clinical risk of any PCa present in
asymptomatic men with raised PSA values, not just those < 20
ng/ml. Although this signature alone was not suitable for
detecting the presence of PCa or its clinical risk in a
population of men having PSA values <20 ng/ml, this T and B
cell phenotypic signature can be used to build highly accurate
machine learning models for predicting the presence of PCa
(when combined with Age) and the clinical risk of any PCa
which is present (when combined with PSA levels).
Using a set of immunophenotyping biomarkers combined
with basic clinical data we have shown it to be possible to develop
machine learning models which can predict the presence of PCa
and its clinical significance, without the need for invasive
biopsies. Inserting the data derived from the analysis of the
peripheral blood from an individual into the proposed tool will
return a prediction about that individual. The proposed models
are based on machine learning methods which can be continually
retrained as more patient data are collected to learn patterns
from a larger population - this will further increase performance.
We expect that the proposed approaches will spare men with
benign prostate disease or low-risk PCa from unnecessary
invasive diagnostic procedures such as TRUS or TPTP biopsy.
We expect that these new approaches could avoid up to 70% of
prostate biopsies, thereby sparing men with benign disease orFrontiers in Immunology | www.frontiersin.org 13low-risk PCa from unnecessary biopsy and significantly reduce
under- and over-diagnosis.
DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online
repositories. The names of the repository/repositories and
accession number(s) can be found below: Mendeley Data:
doi: 10.17632/wmgtzw2w8f.1 (18).
ETHICS STATEMENT
Research Protocols were registered and approved by the National
Research Ethics Service Committee of East Midlands and by the
ResearchandDevelopmentDepartment in theUniversityHospitals
of Leicester NHS Trust. All participants were given information
sheets explaining the nature of the study and all provided informed
consent. Ethical approval for the collection and use of samples from
the TPTP cohort (Project Title: Defining the role of Transperineal
Template-guided prostate biopsy) was given by NRES Committee
East Midlands – Derby 1 (NREC Reference number: 11/EM/3012;
UHL11068). Ethical approval for the collection and use of samples
from the TRUS cohort (Project title: A pilot study to identify gene
fusions in Prostate Cancer) was given by NRES Committee East
Midlands–Derby2 (NRECReference number: 09/H0401/92;UHL
10856). The patients/participants provided their written informed
consent to participate in this study.
AUTHOR CONTRIBUTIONS
GC computationally analyzed the flow cytometry data, prepared
and tested the algorithms, analyzed the results, wrote the first draft,
and made a significant contribution to the preparation of the
manuscript. SM contributed to the preparation, staining and
analysis of the flow cytometry data, and generated the
multidimensional flow cytometry datasets on which the study has
been based. SR, GF, CJ, and SH contributed to the preparation,
staining, and analysis of the flow cytometry data, and generated the
multidimensional flow cytometry datasets on which the study has
been based. MK identified the clinical need, provided access to
clinical samples and clinical data, and made a significant
contribution to the preparation of the manuscript. AP conceived
the study and made a significant contribution to the interpretation
of the data and the preparation of the manuscript. All authors
contributed to the article and approved the submitted version.
FUNDING
The authors acknowledge the financial support of the John and
Lucille van Geest Foundation and the Healthcare and Bioscience
iNet, an ERDF funded initiative managed by Medilink East
Midlands. GC acknowledges the financial support of The
Leverhulme Trust (Research Project Grant RPG-2016-252).
The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.December 2021 | Volume 12 | Article 786828
Cosma et al. Identifying Prostate Cancer Using ImmunophenotypingREFERENCES
1. Stamey TA, Yang N, Hay AR, Mcneal JE, Freiha FS, Redwine E. Prostate-
Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate.
N Engl J Med (1987) 317:909–16. doi: 10.1056/NEJM198710083171501
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al.
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for
Prostate Cancer. N Engl J Med (1991) 324:1156–61. doi: 10.1056/
NEJM199104253241702
3. Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al.
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate
Cancer Mortality: The Cap Randomized Clinical Trial. JAMA (2018)
319:883–95. doi: 10.1001/jama.2018.0154
4. Hugosson J, Roobol MJ, Mansson M, Tammela TLJ, Zappa M, Nelen V, et al.
A 16-Yr Follow-Up of the European Randomized Study of Screening for
Prostate Cancer. Eur Urol (2019) 76:43–51. doi: 10.1016/j.eururo.2019.02.009
5. Serag H, Banerjee S, Saeb-Parsy K, Irving S, Wright K, Stearn S, et al. Risk
Profiles of Prostate Cancers Identified From UK Primary Care Using National
Referral Guidelines. Br J Cancer (2012) 106:436–9. doi: 10.1038/bjc.2011.596
6. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH.
Complication Rates and Risk Factors of 5802 Transrectal Ultrasound-Guided
Sextant Biopsies of the ProstateWithin a Population-Based Screening Program.
Urology (2002) 60:826–30. doi: 10.1016/s0090-4295(02)01958-1
7. Carlson WH, Bell DG, Lawen JG, Rendon RA. Multi-Drug Resistant E.Coli
Urosepsis in Physicians Following Transrectal Ultrasound Guided Prostate
Biopsies - Three Cases Including One Death. Can J Urol (2010) 17:5135–7.
8. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al.
Prospective Evaluation of Prostate Cancer Detected on Biopsies 1, 2, 3 and 4:
When Should We Stop? J Urol (2001) 166:1679–83. doi: 10.1016/S0022-5347
(05)65652-2
9. Nafie S, Pal RP, Dormer JP, Khan MA. Transperineal Template Prostate
Biopsies in Men With Raised PSA Despite Two Previous Sets of Negative
TRUS-Guided Prostate Biopsies. World J Urol (2014) 32:971–5. doi: 10.1007/
s00345-013-1225-x
10. Nafie S, Mellon JK, Dormer JP, Khan MA. The Role of Transperineal
Template Prostate Biopsies in Prostate Cancer Diagnosis in Biopsy Naïve
Men With PSA Less Than 20 Ng.Ml-1. Prostate Cancer Prostatic Dis (2014)
17:170–3. doi: 10.1038/pcan.2014.4
11. Cosma G, Mcardle SE, Reeder S, Foulds GA, Hood S, Khan M, et al.
Identifying the Presence of Prostate Cancer in Individuals With Psa Levels
<20 Ng.Ml–1 Using Computational Data Extraction Analysis of High
Dimensional Peripheral Blood Flow Cytometric Phenotyping Data. Front
Immunol (2017) 8:1771. doi: 10.3389/fimmu.2017.01771Frontiers in Immunology | www.frontiersin.org 1412. Hood SP, Cosma G, Foulds GA, Johnson C, Reeder S, Mcardle SE, et al.
Identifying Prostate Cancer and Its Clinical Risk in Asymptomatic Men Using
Machine Learning of High Dimensional Peripheral Blood Flow Cytometric
Natural Killer Cell Subset Phenotyping Data. Elife (2020) 9. doi: 10.7554/
eLife.50936
13. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick
GA, et al. Biochemical Outcome After Radical Prostatectomy, External
Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically
Localized Prostate Cancer. JAMA (1998) 280:969–74. doi: 10.1001/jama.
280.11.969
14. Bjurlin MA, Taneja SS. Standards for Prostate Biopsy. Curr Opin Urol (2014)
24:155–61. doi: 10.1097/MOU.0000000000000031
15. Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, et al.
Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological
Studies (Second Edition). Eur J Immunol (2019) 49:1457–973. doi: 10.1002/
eji.201970107
16. Schuster M, Paliwal KK. Bidirectional Recurrent Neural Networks. IEEE
Trans Signal Process (1997) 45:2673–81. doi: 10.1109/78.650093
17. Cohen J. Statistical Power Analysis. Curr Dir psychol Sci (1992) 1:98–101. doi:
10.1111/1467-8721.ep10768783
18. Pockley AG, Cosma G, Mcardle SEM, Foulds GA, Hood SP, Reeder S, et al.
Deep Machine Learning of High Dimensional Peripheral Blood Flow
Cytometric Phenotyping Data for Identifying Prostate Cancer and Its
Clinical Risk in Asymptomatic Men, Mendeley Data. (2021). doi: 10.17632/
wmgtzw2w8f.1
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Cosma, McArdle, Foulds, Hood, Reeder, Johnson, Khan and
Pockley. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s) are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.December 2021 | Volume 12 | Article 786828
